Brigitte Michelsen1, Stylianos Georgiadis2, Daniela Di Giuseppe3, Anne G Loft4, Michael J Nissen5, Florenzo Iannone6, Manuel Pombo-Suarez7, Herman Mann8, Ziga Rotar9, Kari K Eklund10, Tore K Kvien11, Maria J Santos12, Bjorn Gudbjornsson13, Catalin Codreanu14, Sema Yilmaz15, Johan K Wallman16, Cecilie H Brahe17, Burkhard Möller18, Ennio G Favalli19, Carlos Sánchez-Piedra20, Lucie Nekvindova21, Matija Tomsic9, Nina Trokovic10, Eirik K Kristianslund11, Helena Santos22, Thorvardur J Löve23, Ruxandra Ionescu14, Yavuz Pehlivan24, Gareth T Jones25, Irene van der Horst-Bruinsma26, Lykke M Ørnbjerg17, Mikkel Østergaard27, Merete L Hetland28. 1. Rigshospitalet, Glostrup, Denmark, Hospital of Southern Norway Trust, Kristiansand, Norway, and Diakonhjemmet Hospital, Oslo, Norway. 2. Rigshospitalet, Glostrup, Denmark. 3. Karolinska Institutet, Stockholm, Sweden. 4. DANBIO Registry and Rigshospitalet, Glostrup, Denmark, and Aarhus University Hospital, Aarhus, Denmark. 5. Geneva University Hospital, Geneva, Switzerland. 6. GISEA Registry and University of Bari, Bari, Italy. 7. Hospital Clinico Universitario, Santiago de Compostela, Spain. 8. Charles University, Prague, Czech Republic. 9. University Medical Centre Ljubljana, Ljubljana, Slovenia. 10. Helsinki University Hospital and ORTON Orthopaedic Hospital of the Orton Foundation, Helsinki, Finland. 11. Diakonhjemmet Hospital, Oslo, Norway. 12. Reuma.pt Registry and Universidade de Lisboa, Lisbon, Portugal. 13. Centre for Rheumatology Research (ICEBIO), University Hospital and University of Iceland, Reykjavik, Iceland. 14. University of Medicine and Pharmacy Carol Davila, Bucharest, Romania. 15. Selcuk University School of Medicine, Selcuklu, Turkey. 16. Lund University, Skåne University Hospital, Lund, Sweden. 17. Rigshospitalet and DANBIO Registry, Glostrup, Denmark. 18. Universitätsklinik für Rheumatologie, Immunologie und Allergologie, Inselspital, Bern, Switzerland. 19. ASST Gaetano Pini-CTO Institute, Milan, Italy. 20. Spanish Society of Rheumatology, Madrid, Spain. 21. Charles University, Prague, Czech Republic, and Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. 22. Reuma.pt Registry and Portuguese Institute of Rheumatology, Lisbon, Portugal. 23. University of Iceland and Landspitali University Hospital, Reykjavik, Iceland. 24. Uludağ University, Bursa, Turkey. 25. University of Aberdeen, Aberdeen, UK. 26. Amsterdam University Medical Centres, VU University Medical Centre, Amsterdam, The Netherlands. 27. Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark. 28. Rigshospitalet and DANBIO Registry, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. METHODS: Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. RESULTS: A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (<2/2-4/>4 years), and varied significantly across the European registries. CONCLUSION: In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.
OBJECTIVE: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. METHODS: Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. RESULTS: A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (<2/2-4/>4 years), and varied significantly across the European registries. CONCLUSION: In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.
Authors: Manuel José Moreno-Ramos; Carlos Sanchez-Piedra; Olga Martínez-González; Carlos Rodríguez-Lozano; Carolina Pérez-Garcia; Mercedes Freire; Cristina Campos; Rafael Cáliz-Caliz; Jerusalem Calvo; Juan María Blanco-Madrigal; Ana Pérez-Gómez; María José Moreno-Martínez; Luis Linares; Fernando Sánchez-Alonso; Carlos Sastré; Isabel Castrejón Journal: Rheumatol Ther Date: 2022-04-25